MAXPHARMA BALTIJA - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 4,344,202 | 4,984,807 | 6,417,908 | 5,693,463 | 5,873,873 | 7,666,197 | 9,067,664 | 9,122,164 |
| Profit before tax | 933,433 | 1,134,741 | 1,483,745 | 1,882,783 | 1,417,587 | 2,061,279 | 3,320,504 | 2,309,641 |
| Net profit | 761,477 | 943,883 | 1,217,212 | 1,589,196 | 1,145,825 | 1,699,023 | 2,807,926 | 1,889,301 |
| Equity | 5,984,989 | 6,928,872 | 7,845,904 | 9,111,927 | 9,887,752 | 11,006,775 | 13,314,701 | 14,004,002 |
| Liabilities | 369,465 | 956,705 | 300,736 | 526,799 | 820,977 | 1,472,589 | 1,050,443 | 1,491,345 |
| Non-current assets | 124,385 | 124,933 | 174,124 | 162,743 | 316,595 | 187,260 | 154,929 | 90,214 |
| Current assets | 6,216,579 | 7,767,427 | 8,007,601 | 9,506,170 | 10,418,205 | 12,330,359 | 14,392,582 | 15,459,176 |
| Total assets | 6,340,964 | 7,892,360 | 8,181,725 | 9,668,913 | 10,734,800 | 12,517,619 | 14,547,511 | 15,549,390 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 345,876 | 457,675 | 775,504 |
| Social insurance contributions | - | - | - | - | - | 80,674 | 86,742 | 112,805 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -14.8% | +14.7% | +28.7% | -11.3% | +3.2% | +30.5% | +18.3% | +0.6% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 12.0% | 12.0% | 14.9% | 16.4% | 10.7% | 13.6% | 19.3% | 12.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 12.7% | 13.6% | 15.5% | 17.4% | 11.6% | 15.4% | 21.1% | 13.5% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 17.5% | 18.9% | 19.0% | 27.9% | 19.5% | 22.2% | 31.0% | 20.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 21.5% | 22.8% | 23.1% | 33.1% | 24.1% | 26.9% | 36.6% | 25.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.1 | 0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 369,719 | 421,252 | 546,205 | 506,086 | 503,473 | 730,114 | 954,491 | 1,004,279 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MAXPHARMA BALTIJA - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-10-18 | 2021-10-19 | 0.90 |
MAXPHARMA BALTIJA - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2025-10-08 | 2025-10-18 | 73.64 |
| 2024-10-09 | 2024-10-09 | 30.59 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MAXPHARMA BALTIJA, UAB (code 111815861) is a Private Limited Liability Company engaged in the wholesale of pharmaceutical and medical goods. In the latest financial year, 2025, the company generated revenue of €9.12M and net profit of €1.89M, resulting in a profit margin of 20.7%. Revenue was broadly stable year on year, increasing by 0.6% in 2025, and it was 19.0% higher than two years earlier. Profitability improved strongly in 2024, when net profit reached €2.81M, before easing in 2025, though it remained above the 2023 level of €1.70M. The balance sheet expanded further, with total assets of €15.55M, equity of €14.00M and liabilities of €1.49M at year-end 2025. The equity ratio stood at 90.1%, while debt-to-equity was 0.11. Operational efficiency remained solid, with asset turnover at 0.59x, ROE at 13.5% and ROA at 12.2%. Based on staff data, revenue per employee was €1.01M and profit per employee was €209.9K.